>
Switch to:

Allergy Therapeutics COGS-to-Revenue

: 0.34 (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Allergy Therapeutics's Cost of Goods Sold for the six months ended in Jun. 2021 was $14.5 Mil. Its Revenue for the six months ended in Jun. 2021 was $42.5 Mil.

Allergy Therapeutics's COGS to Revenue for the six months ended in Jun. 2021 was 0.34.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Allergy Therapeutics's Gross Margin % for the six months ended in Jun. 2021 was 65.95%.


Allergy Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Allergy Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
COGS-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.25 0.25 0.26 0.26

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
COGS-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.23 0.32 0.22 0.34

Allergy Therapeutics COGS-to-Revenue Calculation

Allergy Therapeutics's COGS to Revenue for the fiscal year that ended in Jun. 2021 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=31.004207573633 / 118.2762973352
=0.26

Allergy Therapeutics's COGS to Revenue for the quarter that ended in Jun. 2021 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=14.471248246844 / 42.495091164095
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Allergy Therapeutics's Gross Margin % for the six months ended in Jun. 2021 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 14.471248246844 / 42.495091164095
=65.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Allergy Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)